Sprycel (dasatinib, Bristol-Myers
Squibb) by Ray Sahelian, M.D.
February 24, 2016
Sprycel (dasatinib, Bristol-Myers Squibb) is an oral inhibitor prescription medication of multiple tyrosine kinases approved by the FDA for the treatment of adults in all phases of chronic myeloid leukemia (chronic, accelerated, or myeloid or lymphoid blast phase) with resistance or intolerance to prior therapy, including Gleevec (imatinib mesylate).
Lancet Oncol. Dec 2013. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. The addition of dasatinib to docetaxel did not improve overall survival for chemotherapy-naive men with metastatic castration-resistant prostate cancer. This study does not support the combination of dasatinib and docetaxel in this population of patients.